Samsung C&T (028260) investor relations material

Executive summary

• Q3 sales were KRW 12,008bn and operating profit KRW 1,143bn, both up YoY; net profit declined, while E&C and Bio contributed to operating profit growth.

• Full-year profitability is expected to improve YoY despite anticipated Q4 earnings declines in some business groups.

• Q3 consolidated K-IFRS estimates were prepared before external auditor review and remain subject to change.

Financial highlights

• Sales rose KRW 1,857bn YoY and KRW 13bn QoQ; operating profit increased KRW 149bn YoY and KRW 111bn QoQ.

• Net profit was KRW 801bn, down KRW 84bn YoY and KRW 115bn QoQ; profit before tax was KRW 1,021bn, down KRW 184bn YoY.

• Non-operating results were a KRW 114bn loss, versus KRW 166bn profit in 3Q25; equity-method gains were KRW 27bn.

• 3Q YTD sales were KRW 34,469bn, operating profit KRW 2,895bn and net profit KRW 2,802bn, all higher YoY.

Outlook and guidance

• E&C raised full-year order guidance from KRW 23.5tn to KRW 30.1tn; full-year sales and orders are expected to exceed guidance, and Q4 sales and operating profit to grow QoQ.

• E&C’s Q4 order pipeline is KRW 10tn; High-Tech orders are expected to remain strong in 2027, with significant revenue upside versus 2026.

• Bio Biologics raised full-year sales growth guidance from 15%-20% to 20%; Epis Holdings expects full-year earnings above the prior year.

• T&I expects full-year earnings growth but weaker Q4 results; Fashion, F&B and Leisure expect YoY Q4 sales growth, while Leisure profitability faces renewal-cost pressure.